Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00102167 |
A study to evaluate the safety and effectiveness of Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia for insomnia (a sleep disorder).
Condition | Intervention | Phase |
---|---|---|
Insomnia |
Drug: gaboxadol |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study of MK0928 in Healthy Adult Volunteers Participating in a 4-Hour Phase Advance Model of Transient Insomnia |
Enrollment: | 663 |
Study Start Date: | February 2005 |
Study Completion Date: | December 2005 |
Ages Eligible for Study: | 18 Years to 64 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences ) |
Study ID Numbers: | 2004_092, MK0928-006 |
Study First Received: | January 21, 2005 |
Last Updated: | July 31, 2008 |
ClinicalTrials.gov Identifier: | NCT00102167 |
Health Authority: | United States: Food and Drug Administration |
4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol Sleep Initiation and Maintenance Disorders Mental Disorders Dyssomnias |
Sleep Disorders Healthy Sleep Disorders, Intrinsic |
Nervous System Diseases |